About
CNS treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalMidwest
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
266
By Phase
PHASE1: 2PHASE3: 3PHASE1/PHASE2: 1
By Status
COMPLETED: 5SUSPENDED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07119073Lead Sponsor
In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)
PHASE1Completed
25 participants
Started: Oct 31, 2024 · Completed: Dec 27, 2024
NCT05924594Lead Sponsor
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
PHASE3Suspended
45 participants
Started: Jul 31, 2023 · Completed: Mar 31, 2026
NCT05286762Lead Sponsor
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
PHASE3Completed
103 participants
Started: Jul 25, 2023 · Completed: Jan 24, 2024
NCT05631626Lead Sponsor
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
PHASE3Completed
21 participants
Started: Dec 29, 2022 · Completed: Jun 13, 2023
NCT04449250Lead Sponsor
Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects
PHASE1Completed
27 participants
Started: Sep 14, 2022 · Completed: Oct 14, 2022
Locations (1)
Headquarters
Kansas City, KS, United States
Map
Loading map...